Form 4: Acadia Pharmaceuticals Insider Sells Shares

James Kihara, Principal Accounting Officer at Acadia Pharmaceuticals, reported transactions involving the sale of common stock.

Summary

• James Kihara, Principal Accounting Officer at Acadia Pharmaceuticals Inc., reported transactions on April 5, 2026, and April 7, 2026.
• On April 5, 2026, 2,010 restricted stock units were acquired.
• On April 7, 2026, 1,030 shares of common stock were disposed of at a weighted average price of $22.20, with prices ranging from $22.07 to $22.20.
• These sales were made to cover withholding taxes and tax-related items associated with the vesting of restricted stock units.
• The transactions are intended to comply with Rule 10b5-1(c) for affirmative defense conditions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transactions are routine for tax purposes and do not necessarily indicate a change in the insider's view of the company's prospects.

Negatives

• Insider selling of company stock can sometimes be perceived negatively by the market, although in this case it is for tax withholding purposes.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The nature of this transaction, related to tax withholding, is a common occurrence for executives receiving equity compensation.

Stakeholder Impact

• Shareholders: The sale of shares by an insider for tax purposes is a routine event and typically has minimal direct impact on the share price, though any insider selling can be scrutinized.

Key Dates

Keywords

Form 4, Insider Transaction, Acadia Pharmaceuticals, Stock Sale, Restricted Stock Units, Tax Withholding, Rule 10b5-1(c)